Indraprastha Medical Corporation Ltd (INDRAMEDCO) — shareholding pattern, promoter holding, financials and share price
About Indraprastha Medical Corporation Ltd (INDRAMEDCO)
Indraprastha Medical Corporation Ltd operates in the Hospital industry, within the Healthcare sector. It trades on the NSE as INDRAMEDCO and on the BSE under scrip code 532150. Its ISIN is INE681B01017.
Incorporated in 1988 as a JV between Apollo Hospitals Enterprise Ltd. (AHEL) and the Delhi Government, Indraprastha Medical Corporation Ltd. is a super speciality tertiary care hospital in New Delhi. The Co. currently has 52 speciality departments. [1]
Indraprastha Medical Corporation Limited provides high-quality, comprehensive hospital services, enhancing patients' quality of life.
The company has established India's first corporate hospital, a multi-disciplinary super-speciality tertiary care hospital in New Delhi.
Listed peers in Hospital: Artemis Medicare Services Ltd, Dr Agarwals Eye Hospital Ltd, KMC Speciality Hospitals (India) Ltd, Shalby Ltd, Unihealth Hospitals Ltd, GPT Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹380.1 a share on 10 Jul 2026, Indraprastha Medical Corporation Ltd (INDRAMEDCO) was valued at a price-to-earnings ratio of 18.98x against an industry P/E of 61.73x and a price-to-book of 5.84x on a book value of ₹65.09 per share as of Mar 2025. Solomo computes return on equity of 30.77% and return on capital employed of 40.04% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 18.98x
- Industry P/E
- 61.73x
- P/B
- 5.84x
- EPS (TTM)
- ₹20.03
- Book value / share
- ₹65.09
- ROE
- 30.77%
- ROCE
- 40.04%
- ROA
- 21.56%
- Debt / equity
- 0.05x
- Dividend yield
- 1.18%
- EBITDA margin
- 19.94%
- 52-week range
- ₹342.35 – ₹640.05
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Indraprastha Medical Corporation Ltd (INDRAMEDCO) reported revenue of ₹1,483 crore, net profit of ₹184 crore and earnings per share of ₹20.03. That compares with revenue of ₹1,356 crore and net profit of ₹161 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹365 crore and net profit ₹42 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 888 | 1,099 | 1,245 | 1,356 | 1,483 |
| Net profit (₹ cr) | 59 | 86 | 124 | 161 | 184 |
| EPS (₹) | 6.39 | 9.4 | 13.52 | 17.56 | 20.03 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 6.72% | 10.30% | 15.16% | 8.97% |
| Profit growth | 23.31% | 29.84% | 40.04% | 29.87% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 51% of Indraprastha Medical Corporation Ltd (INDRAMEDCO) (unchanged from the previous quarter), foreign institutional investors (FII) hold 2.77% and domestic institutional investors (DII) hold 0.59%. Market capitalisation was ₹3,484 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Vanaja Sundar Iyer 1.97%, Emedlife Insurance Broking Services Limited 1.7%, HUF 1.35%, Citadel Research And Solutions Limited 1.29%, INVESTOR EDUCATION PROTECTION FUND 1.09%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 51% | - | 2.77% | 0.59% | 49% |
| Mar 2026 | 51% | - | 2.44% | 0.88% | 49% |
| Dec 2025 | 51% | - | 2.73% | 0.83% | 49% |
| Sep 2025 | 51% | - | 2.41% | 3.51% | 49% |
| Jun 2025 | 51% | - | 2.72% | 3.56% | 49% |
| Mar 2025 | 51% | - | 2.94% | 3.56% | 49% |
| Dec 2024 | 51% | - | 2.88% | 3.19% | 49% |
| Sep 2024 | 51% | - | 2.64% | 3.2% | 49% |